Prostate Cancer Clinical Trial

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Must have histologically or cytologically confirmed adenocarcinoma of the prostate
Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria:

Prior treatment with an androgen receptor (AR) degrader
Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

122

Study ID:

NCT04428788

Recruitment Status:

Recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 22 Locations for this study

See Locations Near You

UAB
Birmingham Alabama, 35249, United States More Info
Arnab Basu, Site 118
Contact
323-865-3000
Stanford University
Stanford California, 94305, United States More Info
Sandy Srinivas, Site 116
Contact
650-725-2078
Sibley Memorial Hospital
Washington District of Columbia, 20016, United States More Info
Michael Carducci, Site 208
Contact
410-614-3977
M.D. Anderson Cancer Center
Orlando Florida, 32806, United States More Info
Ana Aparicio, Site 119
Contact
832-312-6124
Florida Cancer Specialists
Sarasota Florida, 34232, United States
Florida Cancer Specialists
Sarasota Florida, 34232, United States More Info
Manish Patel, Site 103
Contact
941-377-9993
Emory University.
Atlanta Georgia, 30303, United States More Info
Bradley Carthon, Site 114
Contact
404-686-8210
University of Chicago
Chicago Illinois, 60637, United States
Johns Hopkins
Baltimore Maryland, 21287, United States
Johns Hopkins
Baltimore Maryland, 21287, United States More Info
Michael Carducci, Site 108
Contact
410-614-3977
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Atish Choudhury, Site 104
Contact
University Of Michigan Cancer Center
Ann Arbor Michigan, 48109, United States More Info
Zachery Reichert, Site 117
Contact
815-353-5419
START Midwest
Grand Rapids Michigan, 49546, United States
START Midwest
Grand Rapids Michigan, 49546, United States More Info
Nehal Lakhani, Site 102
Contact
Memorial Sloan-Kettering Cancer Center
New York New York, 10021, United States
Mount Sinai - Icahn School of Medicine
New York New York, 10029, United States More Info
Matthew Galsky, Site 112
Contact
212-824-8583
Mount Sinai Doctors Dermatology
New York New York, 10029, United States
Columbia University
New York New York, 10032, United States More Info
Karie Runcie, Site 109
Contact
516-424-4205
Memorial Sloan Kettering cancer Center
New York New York, 10065, United States More Info
Dana Rathkopf, Site 105
Contact
Duke University Medical Center
Durham North Carolina, 27710, United States
Duke University Medical Center
Durham North Carolina, 27710, United States More Info
Andrew Armstrong, Site 106
Contact
919-668-8797
Abramson Cancer Center
Philadelphia Pennsylvania, 19104, United States
Abramson Cancer Center
Philadelphia Pennsylvania, 19104, United States More Info
Vivek Narayan, Site 113
Contact
215-360-0706
UT Southwestern
Dallas Texas, 75235, United States
Ut Southwestern
Dallas Texas, 75235, United States More Info
Kevin Courtney, Site 107
Contact
214-648-1948
South Texas Accelerated Research Therapeutics (START)
San Antonio Texas, 78229, United States More Info
Drew Rasco, Site 101
Contact
210-593-5250
South Texas Accelerated Research Therapeutics
San Antonio Texas, 78229, United States
Fred Hutchinson Cancer Research Center
Seattle Washington, 98109, United States More Info
Jessica Hawley, Site 115
Contact
000-000-0000
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53705, United States
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States More Info
Hamid Emamekhoo, Site 111
Contact
513-862-1400

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

122

Study ID:

NCT04428788

Recruitment Status:

Recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.